Answers are grounded in this paper and cite their sources.
Constitutional Mismatch Repair Deficiency (CMMRD) is a rare autosomal recessive cancer predisposition syndrome caused by biallelic pathogenic variants in the mismatch repair genes MLH1 , MSH2 , MSH6 , or PMS2 , conferring an extremely high risk of early-onset, multi-organ malignancy. Diagnosis is frequently delayed by phenotypic overlap with other neurocutaneous disorders and by atypical tumor presentations that hinder consistent application of the C4CMMRD scoring criteria. We retrospectively reviewed two pediatric cases illustrating this diagnostic delay. In Case 1, a homozygous MSH6 variant was molecularly confirmed four years after hematopoietic stem cell transplantation for relapsed T-cell lymphoblastic lymphoma, the diagnosis having been anchored for years to a clinical diagnosis of Tuberous Sclerosis Complex despite pigmentary skin findings and negative TSC1 / TSC2 testing. In Case 2, the patient developed three metachronous malignancies — Burkitt lymphoma, osteosarcoma, and rectal adenocarcinoma — over approximately sixteen years; because germline PMS2 testing could not be performed after allogeneic transplantation, CMMRD was diagnosed by family-based and tumor-based evidence. Across both cases, a consistent constellation of oncologic (early-onset, multiple, or atypical malignancies), dermatologic (café-au-lait macules and other pigmentary alterations), and neurologic (developmental venous anomalies) red flags were present from an early stage. Applying the original C4CMMRD and the revised ERN GENTURIS scoring criteria retrospectively, Case 1 met the testing threshold at the first cancer diagnosis with both systems. Case 2 met it at the first diagnosis only with the original criteria (3 points); with GENTURIS (2 points) it was reached only after a subsequent malignancy. Giving atypical Burkitt lymphoma more weight, as is done for T-lymphoblastic lymphoma (2 points), would have brought Case 2 to the threshold at the first diagnosis under GENTURIS as well. We propose a pattern-based diagnostic flowchart integrating oncology, dermatology, and neuroradiology to support earlier recognition and application of the scoring criteria across these three domains. Early, cross-specialty pattern recognition may substantially shorten the diagnostic interval in CMMRD, with direct implications for cancer surveillance and family risk assessment.
No takes yet. Share an insight, caveat, or question.
Romani et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: